FIGURE 4 from LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency

LP-184 is effective in HRD TNBC PDX models regardless of their sensitivity to PARPi. LP-184 treatment (4 mg/kg i.v.) on days 0, 2, 4, 6, 8 and 16, 18, 20, 22, 24 in HRD TNBC PDX models showing HBCx-24 (PARPi resistant) tumor growth curves (mean ± SD) for vehicle versus treatment arms (A), T168 (PARPi sensitive) tumor growth curves (mean ± SD) for vehicle versus treatment arms (B), and Waterfall plot illustrating tumor regression in all 10 LP-184–treated PDX models (C).